Cidara Therapeutics Inc (NASDAQ: CDTX) started the day on Wednesday, with a price increase of 5.15% at $0.92, before settling in for the price of $0.88 at the close. Taking a more long-term approach, CDTX posted a 52-week range of $0.59-$1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was 33.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -141.07%. This publicly-traded company’s shares outstanding now amounts to $90.62 million, simultaneously with a float of $81.35 million. The organization now has a market capitalization sitting at $83.38 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7581, while the 200-day Moving Average is $0.8500.
Cidara Therapeutics Inc (CDTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Cidara Therapeutics Inc’s current insider ownership accounts for 10.23%, in contrast to 29.71% institutional ownership. According to the most recent insider trade that took place on Mar 11 ’24, this organization’s CHIEF SCIENTIFIC OFFICER sold 21,029 shares at the rate of 0.67, making the entire transaction reach 14,085 in total value, affecting insider ownership by 258,681. Preceding that transaction, on Mar 11 ’24, Company’s Chief Medical Officer sold 20,662 for 0.67, making the whole transaction’s value amount to 13,839. This particular insider is now the holder of 347,095 in total.
Cidara Therapeutics Inc (CDTX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2023, the organization reported -$0.09 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.16) by $0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cidara Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -141.07% and is forecasted to reach -0.62 in the upcoming year.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Let’s observe the current performance indicators for Cidara Therapeutics Inc (CDTX). It’s Quick Ratio in the last reported quarter now stands at 1.55. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.47.
In the same vein, CDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.38, a figure that is expected to reach -0.07 in the next quarter, and analysts are predicting that it will be -0.62 at the market close of one year from today.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
If we take a close look at the recent performances of Cidara Therapeutics Inc (NASDAQ: CDTX), its last 5-days Average volume was 1.44 million that shows progress from its year to date volume of 0.67 million. During the previous 9 days, stock’s Stochastic %D was recorded 43.31% While, its Average True Range was 0.1404.
Raw Stochastic average of Cidara Therapeutics Inc (CDTX) in the period of the previous 100 days is set at 52.17%, which indicates a major rise in contrast to 40.02% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 131.08% that was higher than 69.24% volatility it exhibited in the past 100-days period.
